Abstract
Abstract The authors use an historical case‐study of a single line of therapeutic development (in vaccines and serum antitoxins) to bring out salient aspects of the shifting sources of innovation in the pharmaceutical industry during the twentieth century. Their emphasis is on the complex relationships that have evolved between three companies ‐ Mulford, Sharp & Dohme, and Merck & Co., Inc. ‐ and the loosely integrated networks of public, profit‐making, and non‐profit institutions that have been central to the process of innovation in this science‐based industry. Galambos and Sturchio enumerate the characteristics of pharmaceutical organisations that have remained successful innovators over the long term.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
